- Home
- LXRX vs XOMA Comparison
LXRX vs XOMA Comparison
Compare LXRX & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- XOMA
- Stock Information
- Founded
- LXRX 1995
- XOMA 1981
- Country
- LXRX United States
- XOMA United States
- Employees
- LXRX N/A
- XOMA N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- XOMA Health Care
- Exchange
- LXRX Nasdaq
- XOMA Nasdaq
- Market Cap
- LXRX 352.5M
- XOMA 355.6M
- IPO Year
- LXRX 2000
- XOMA N/A
- Fundamental
- Price
- LXRX $0.75
- XOMA $27.14
- Analyst Decision
- LXRX Buy
- XOMA Strong Buy
- Analyst Count
- LXRX 2
- XOMA 2
- Target Price
- LXRX $6.00
- XOMA $81.50
- AVG Volume (30 Days)
- LXRX 4.9M
- XOMA 30.4K
- Earning Date
- LXRX 11-12-2024
- XOMA 11-07-2024
- Dividend Yield
- LXRX N/A
- XOMA N/A
- EPS Growth
- LXRX N/A
- XOMA N/A
- EPS
- LXRX N/A
- XOMA N/A
- Revenue
- LXRX $5,229,000.00
- XOMA $21,606,000.00
- Revenue This Year
- LXRX $886.38
- XOMA $509.54
- Revenue Next Year
- LXRX $181.58
- XOMA $26.20
- P/E Ratio
- LXRX N/A
- XOMA N/A
- Revenue Growth
- LXRX 886.60
- XOMA 389.82
- 52 Week Low
- LXRX $0.62
- XOMA $16.00
- 52 Week High
- LXRX $3.73
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- LXRX 38.05
- XOMA 34.87
- Support Level
- LXRX $0.72
- XOMA $27.01
- Resistance Level
- LXRX $0.85
- XOMA $30.86
- Average True Range (ATR)
- LXRX 0.09
- XOMA 1.25
- MACD
- LXRX 0.03
- XOMA -0.54
- Stochastic Oscillator
- LXRX 33.10
- XOMA 1.63
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.